Catalent to buy Paragon Bioservices for $1.2 billion: WSJ
Drug developer Catalent Inc has agreed to buy privately held Paragon Bioservices Inc for $1.2 billion, the Wall Street Journal reported on Sunday, citing people familiar with the matter.
from Reuters: Health News https://reut.rs/2VIRBmp
http://bit.ly/2zwRqiM